利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.018 秒)

    Lysophospholipids as biomarkers of ovarian cancer
    3.
    发明授权
    Lysophospholipids as biomarkers of ovarian cancer 有权
    溶血磷脂作为卵巢癌生物标志物

    公开(公告)号：US07964408B1

    公开(公告)日：2011-06-21

    申请号：US10908484

    申请日：2005-05-13

    申请人： Rebecca Sutphen

    发明人： Rebecca Sutphen

    IPC分类号： G01N33/00

    CPC分类号： G01N33/57449 ,  C12Q1/6851 ,  C12Q1/6874 ,  C12Q1/6886 ,  G01N33/92 ,  G01N2405/04 ,  G01N2405/06 ,  G01N2560/00

    摘要： A method of using a bioactive lysophospholipid (LL) as a biomarker for detecting the presence and recurrence of ovarian cancer. Subspecies of LL, such as lysophosphatidic acid (LPA), lysophosphatidylinositol (LPI), lysophosphatidylcholine (LPC), and lysosphingolipid sphinsosine-1-phosphate (S1P), are used alone or in conjunction to increase the specificity and sensitivity of the assay.

    摘要翻译： 使用生物活性溶血磷脂（LL）作为生物标志物检测卵巢癌存在和复发的方法。 单独或联合使用LL的亚种，如溶血磷脂酸（LPA），溶血磷脂酰肌醇（LPI），溶血磷脂酰胆碱（LPC）和溶血神经鞘脂肌球蛋白-1-磷酸酯（S1P）），以增加测定的特异性和灵敏度。

    Novel gold nanoparticle aggregates and their applications
    4.
    发明申请
    Novel gold nanoparticle aggregates and their applications 有权
    新型金纳米颗粒聚集体及其应用

    公开(公告)号：US20120142119A1

    公开(公告)日：2012-06-07

    申请号：US13199563

    申请日：2011-09-03

    申请人： Jin Zhang ,  Adam Schwartzberg ,  Thaddeus Norman ,  Tammy Y. Oshiro ,  Christian D. Grant ,  Rebecca Sutphen ,  Leo Seballos ,  Yi Zhang ,  Claire Gu

    发明人： Jin Zhang ,  Adam Schwartzberg ,  Thaddeus Norman ,  Tammy Y. Oshiro ,  Christian D. Grant ,  Rebecca Sutphen ,  Leo Seballos ,  Yi Zhang ,  Claire Gu

    IPC分类号： G01N21/65 ,  B82Y15/00

    CPC分类号： G01N33/54346 ,  G01N21/658 ,  G01N33/54313 ,  G01N33/553 ,  G01N33/585 ,  G01N33/587 ,  G01N33/6854

    摘要： The invention is drawn to a method of using nanoparticle aggregates to form sensors and optical filters. Properly sized (60 and 200 nm) nanoparticle aggregates with cores having a sulfur-oxygen molecular species and a shell with a surface in contact with the core are obtained. Those nanoparticle aggregates have a first resonance profile to wavelengths between 350 nm and 1075 nm. A modified resonance profile for those nanoparticle aggregates is determined. The nanoparticle aggregates are then selectively sized by irradiating them with electromagnetic energy at sufficient intensity and spectral content to modify the first resonance profile towards the modified resonance profile. The resulting nanoparticle aggregates can be used as sensors or optical filters at a selected wavelength.

    摘要翻译： 本发明涉及使用纳米颗粒聚集体形成传感器和滤光器的方法。 获得具有硫 - 氧分子种类的芯和具有与芯接触的表面的壳的适当尺寸（60和200nm）纳米颗粒聚集体。 那些纳米颗粒聚集体具有在350nm和1075nm之间的波长的第一共振分布。 确定这些纳米颗粒聚集体的改性共振谱。 然后通过以足够的强度和光谱含量的电磁能照射纳米颗粒聚集体来选择性地调整纳米颗粒聚集体，以改变朝向修饰的共振分布的第一共振分布。 所得到的纳米颗粒聚集体可以用作选定波长的传感器或光学滤光器。

    Methods for detecting or monitoring cancer using LPE as a marker
    5.
    发明授权
    Methods for detecting or monitoring cancer using LPE as a marker 有权
    使用LPE作为标记检测或监测癌症的方法

    公开(公告)号：US08133736B2

    公开(公告)日：2012-03-13

    申请号：US12775958

    申请日：2010-05-07

    申请人： Lian Shan ,  Lorelei D. Davis ,  Rebecca Sutphen

    发明人： Lian Shan ,  Lorelei D. Davis ,  Rebecca Sutphen

    IPC分类号： G01N33/92 ,  G01N33/48

    CPC分类号： G01N33/57449 ,  G01N2800/56 ,  Y10T436/163333

    摘要： A method of detecting a cancer, such as ovarian cancer, in a test subject including (a) determining the amount of a lysophosphatidyl ethanolamine in a sample of a bodily fluid taken from the test subject, and (b) comparing the amount of the lysophosphatidyl ethanolamine in the sample of the bodily fluid taken from the test subject to a range of amounts of the lysophosphatidyl ethanolamine found in samples of the bodily fluid taken from a group of normal subjects of the same species as the test subject and lacking the cancer, such as ovarian cancer, whereby a change in the amount of the lysophosphatidyl ethanolamine in the sample of the bodily fluid from the test subject indicates the presence of the cancer, such as ovarian cancer.

    摘要翻译： 一种检测受检对象中癌症如卵巢癌的方法，包括（a）测定取自受试者的体液样品中的溶血磷脂酰乙醇胺的量，和（b）比较溶血磷脂酰胆碱 将来自受检对象的体液样品中的乙醇胺溶解于从与测试对象相同种类的正常受试者组中获得的体液样品中发现的溶血磷脂酰乙醇胺的量的范围，并且缺乏癌症 作为卵巢癌，其中来自受试对象的体液样品中溶血磷脂酰乙醇胺的量的变化表明存在癌症，例如卵巢癌。

    METHODS FOR DETECTING OR MONITORING CANCER USING LPE AS A MARKER
    8.
    发明申请
    METHODS FOR DETECTING OR MONITORING CANCER USING LPE AS A MARKER 有权
    使用LPE作为标记检测或监测癌症的方法

    公开(公告)号：US20110059543A1

    公开(公告)日：2011-03-10

    申请号：US12775958

    申请日：2010-05-07

    申请人： Lian Shan ,  Lorelei D. Davis ,  Rebecca Sutphen

    发明人： Lian Shan ,  Lorelei D. Davis ,  Rebecca Sutphen

    IPC分类号： G01N33/50

    CPC分类号： G01N33/57449 ,  G01N2800/56 ,  Y10T436/163333

    摘要： A method of detecting a cancer, such as ovarian cancer, in a test subject including (a) determining the amount of a lysophosphatidyl ethanolamine in a sample of a bodily fluid taken from the test subject, and (b) comparing the amount of the lysophosphatidyl ethanolamine in the sample of the bodily fluid taken from the test subject to a range of amounts of the lysophosphatidyl ethanolamine found in samples of the bodily fluid taken from a group of normal subjects of the same species as the test subject and lacking the cancer, such as ovarian cancer, whereby a change in the amount of the lysophosphatidyl ethanolamine in the sample of the bodily fluid from the test subject indicates the presence of the cancer, such as ovarian cancer.

    摘要翻译： 一种检测受检对象中癌症如卵巢癌的方法，包括（a）测定取自受试者的体液样品中的溶血磷脂酰乙醇胺的量，和（b）比较溶血磷脂酰胆碱 将来自受检对象的体液样品中的乙醇胺溶解于从与测试对象相同种类的正常受试者组中获得的体液样品中发现的溶血磷脂酰乙醇胺的量的范围，并且缺乏癌症 作为卵巢癌，其中来自受试对象的体液样品中溶血磷脂酰乙醇胺的量的变化表明存在癌症，例如卵巢癌。

    METHODS FOR DETECTING OR MONITORING CANCER USING LPC AS A MARKER
    9.
    发明申请
    METHODS FOR DETECTING OR MONITORING CANCER USING LPC AS A MARKER 审中-公开
    使用LPC作为标记检测或监测癌症的方法

    公开(公告)号：US20100291690A1

    公开(公告)日：2010-11-18

    申请号：US12734117

    申请日：2008-11-05

    申请人： Lian Shan ,  Rebecca Sutphen

    发明人： Lian Shan ,  Rebecca Sutphen

    IPC分类号： G01N33/487

    CPC分类号： G01N33/57484 ,  G01N33/57449 ,  G01N2405/04 ,  G01N2800/56

    摘要： A method of detecting a cancer, such as ovarian cancer, in a test subject including (a) determining the amount of a lysophosphatidyl choline in a sample of a bodily fluid taken from the test subject, and (b) comparing the amount of the lysophosphatidyl choline in the sample of the bodily fluid taken from the test subject to a range of amounts of lysophosphatidyl choline found in samples of the bodily fluid taken from a group of normal subjects of the same species as the test subject and lacking the cancer, such as ovarian cancer, whereby a change in the amount of the lysophosphatidyl choline in the sample of the bodily fluid taken from the test subject indicates the presence of the cancer, such as ovarian cancer.

    摘要翻译： 一种检测受检对象中癌症如卵巢癌的方法，包括（a）测定取自受试者的体液样品中的溶血磷脂酰胆碱的量，和（b）比较溶血磷脂酰胆碱 从测试受试者取得的体液样品中的胆碱在从与测试对象相同种类的正常受试者组中获得的体液样品中发现的溶血磷脂酰胆碱的量的范围内，并且缺乏癌症，例如 卵巢癌，其中取自受试者的体液样品中的溶血磷脂酰胆碱的量的变化表明存在癌症，例如卵巢癌。